Skye Bioscience Inc.’s Post

HiRO ANZ achieved rapid site activation and met the initial recruitment target of 450 participants within the 5-month period for a Phase 2 obesity clinical trial. Our collaboration with sites to initiate pre-screening and strategic planning allowed us to adapt quickly, even as the target increased to 495 participants over 7 months. Learn more about our recruitment strategies here: https://lnkd.in/gJZtUBP4 #ClinicalTrials #PatientRecruitment #HiROANZ #HealthcareInnovation

Last week at Medicon Valley Alliance DiaUnion held its Screening for Type 1 Diabetes symposium. We had exciting talks about type 1 diabetes, screening, prevention and health economics, as well as learning about the background, the results so far and the future ambitions of DiaUnion. All supported by expert panels joined by people living with T1D, researchers, patient organizations and industry. Key take-aways included: - For the first time since the invention of insulin more than 100 years ago, new treatments of T1D may be in the horizon. - Novel therapies that delay the clinical onset of T1D are under development, one of them, already approved by FDA in the US, delays clinical onset by more than 2 years on average. - Lack of screening programs constitute a bottleneck in identifying individuals at risk for T1D. - DiaUnion is establishing a large scale screening program with the ambition to offer screening to all as part of the public health services. Thanks to: Anette Steenberg Daniel Agardh Elin Cederbrant Flemming Pociot Jesper Johannesen Kristian Handberg Mikkelsen Manuela Battaglia Sofie Persson Sophie Hindkjær Stephan Bouman Tanja Thybo Tine Filges Åke Lernmark #type1diabetes #overgransen

Phentermine, Naltrexone/Bupropion, Liraglutide 3mg, Orlistat, Semaglutide 2.4mg are NPRA approved and CPG listed AOMs. . But, they are not listed in the KKM formulary. Therefore, I frequently received this type of letter requesting an essay reply to help the patients working as government servants get reimbursement (pay & claim) and/or prior authorization for AOMs. . If 🇲🇾 is serious in treating obesity as a disease, and make it accessible (majority of patients that use this health benefits are B40s), we need to have some of the AOMs, if not all, in the KKM formulary. . It's still an exciting task for me to draft these essays for my patients' benefit, but I wonder how long I can last. 🙏💪 After 4 years, still enjoyable la, just give me some time. 🐢 . On the other hand, there are patients who upfront gave up when they received this reply letter thinking it's so much of a hassle to the attending doctors and also anxious of final rejection from KKM. Tak pernah cuba, tidak tahu. . I know what I signed up for when I specialize in obesity medicine. 🤭🤗🫂

I am very happy to start 2024 with this manuscript being published. Bringing rich and robust RWE in rare disease from our key questions to the publication can be a long and complex journey, but we learn so much along the way. Thank you to the team! Nadia Pillai, Audrey Muller, Rafael Sauter, Allan Lawrie, Fernando Exposto, Louise Raiteri, Neil Hamilton, David Kiely Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare disease characterised by obstruction of the pulmonary arteries. Left untreated, mortality is higher in CTEPH than in many common cancers. CTEPH is challenging to diagnose due to non-specific initial symptoms and patients often present at an advanced stage. We conducted a retrospective observational study to generate real-world evidence from a UK high-volume PH referral centre linked with data from the National Health Service (NHS) Hospital Episode Statistics (HES) database. Our results confirm that the economic burden of CTEPH is high and that health care resource use (HCRU) and costs are higher in intermediate-risk and high-risk patients. Our study supports the use of a risk stratification approach used in pulmonary arterial hypertension in a large cohort of patients with CTEPH, demonstrating differences in survival in the three risk bands at diagnosis.  This study adds to a limited literature describing the economic burden of CTEPH, with data available prediagnosis and postdiagnosis and by risk status at diagnosis. Whether treatment strategies aimed at achieving, where possible, a low-risk profile in patients with CTEPH can improve patient outcomes requires further research. In addition, the diagnosis of CTEPH reduces unplanned HCRU (via A&E visits) among operated and not-operated patients, regardless of risk group, emphasising the importance of achieving a diagnosis and its positive impact on health-seeking behaviour.

We presented "Extensive right-sided endocarditis in double-chamber right ventricle presented with leukocytoclastic vasculitis" Akram Nakhaee, Parisa Koohsari, Mehrzad Rahmanian, Akram Sardari, Roya Parkhideh, Farnoosh Larti Clinical Case Reports Volume 11, Issue 3 We report a patient with a double-chambered right ventricle (DCRV) and extensive right-sided infective endocarditis (IE) with an initial presentation of leukocytoclastic vasculitis.

The heterogeneity of #diabetes underscores the need for more precise diagnostic, prevention and treatment strategies than exist today. The application of #precisionmedicine in diabetes prevention and care offers hopeful prospects for reducing the disease's complications and fatalities. Read the second international consensus report on precision diabetes medicine, coauthored by Harvard Pilgrim Health Care Institute's Dr. Marie-France Hivert. The international team: ✔️ Summarizes the findings from a systematic evidence review across the 4 key pillars of precision medicine ✔️ Addresses key questions about the translation of precision medicine research into practice ✔️ Reveals opportunities for the immediate or near-term clinical implementation of precision diabetes medicine ✔️ Exposes important gaps in knowledge, focusing on the need to obtain new clinically relevant evidence and ✔️ Outlines key milestones for broad clinical implementation of precision medicine https://buff.ly/46w6OdU

𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗽𝗲𝗿𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲 𝗺𝗮𝘁𝘁𝗲𝗿𝘀! 👈 It is well established that pulmonary hypertension (PH) places a substantial burden on patients' health-related quality of life (HRQoL). As more effective treatments have been developed for this condition, evaluating treatment benefit based on experiences reported by patients regarding their well-being and physical, social, economic and emotional functioning has increased. Patient perspective matters and it should be a mold for every initiative in the field of PH research, diagnosis and treatment. How you feel should determine the future of PH research and treatment. The importance of patient associations in this regard is becoming more prominent. ➡Find out more about PROMs: https://lnkd.in/ecD2Q6Na ➡Read more abut PHA Europe’s initiative: phaeurope.org 🔎Join our premier virtual platform for PH patients and stakeholders, an online place that connects hearts and empowers minds: belaircenter.info #pulmonaryhypertension #patientcare #accesstocare #awareness #patientempowerment #patientliteracy #PROMs #HRQoL #PAH #CTEPH #research #medicine

An original article about #NAFLD related #HCC growth rates and their clinical outcomes by Prof. Jihane N. Benhammou's team. Full text: https://lnkd.in/gx8WJ2bC PDF: https://lnkd.in/gkCmVKE8 In the current study, the team aimed to derive HCC TGR in a NAFLD sub-cohort and contemporaneously compare to HCC TGR in HBV and HCV sub-cohorts to determine how etiology-specific TGR impacted clinical outcomes, including overall survival based on treatment modalities. Hope this article will be helpful to your recent study! Anna Fracanzani Paola Dongiovanni Christian Labenz Tim Greten Seung Woon Paik Romilda Cardin Takehara Tetsuo

Want to learn why clinical inertia matters in #Obesity care and how you can enlist primary care to overcome it? Join Jaime Almandoz, MD, MBA, FTOS, and Angela Fitch MD, FACP, FOMA, Dipl. ABOM, on October 15th at 6:30 PM CDT during #OW2023 to do just that! https://lnkd.in/eh8JTN9U #MedEd This activity is supported by an educational grant from Eli Lilly and Company.

Register with the link below to hear my wife present on the topic of obesity.